JP2019523236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523236A5 JP2019523236A5 JP2018567628A JP2018567628A JP2019523236A5 JP 2019523236 A5 JP2019523236 A5 JP 2019523236A5 JP 2018567628 A JP2018567628 A JP 2018567628A JP 2018567628 A JP2018567628 A JP 2018567628A JP 2019523236 A5 JP2019523236 A5 JP 2019523236A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- beta
- lactamase
- billed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 108090000204 Dipeptidase 1 Proteins 0.000 claims 10
- 102000006635 beta-lactamase Human genes 0.000 claims 10
- 239000002775 capsule Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 244000005700 microbiome Species 0.000 claims 6
- 239000003242 anti bacterial agent Substances 0.000 claims 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 5
- 229940127249 oral antibiotic Drugs 0.000 claims 5
- 241000193163 Clostridioides difficile Species 0.000 claims 4
- 230000003115 biocidal effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229920003143 Eudragit® FS 30 D Polymers 0.000 claims 3
- 230000002411 adverse Effects 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 239000008188 pellet Substances 0.000 claims 3
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 229920003134 Eudragit® polymer Polymers 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- 239000003781 beta lactamase inhibitor Substances 0.000 claims 2
- 229940126813 beta-lactamase inhibitor Drugs 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010011409 Cross infection Diseases 0.000 claims 1
- 208000005156 Dehydration Diseases 0.000 claims 1
- 229920003141 Eudragit® S 100 Polymers 0.000 claims 1
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 239000000337 buffer salt Substances 0.000 claims 1
- 229960003324 clavulanic acid Drugs 0.000 claims 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical group OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000004840 megacolon Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 230000001839 systemic circulation Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022074289A JP7530933B2 (ja) | 2016-06-28 | 2022-04-28 | 経口抗生物質からのマイクロバイオーム防御 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355599P | 2016-06-28 | 2016-06-28 | |
| US62/355,599 | 2016-06-28 | ||
| PCT/US2017/039672 WO2018005606A1 (en) | 2016-06-28 | 2017-06-28 | Microbiome protection from oral antibiotics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022074289A Division JP7530933B2 (ja) | 2016-06-28 | 2022-04-28 | 経口抗生物質からのマイクロバイオーム防御 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523236A JP2019523236A (ja) | 2019-08-22 |
| JP2019523236A5 true JP2019523236A5 (enExample) | 2020-07-30 |
| JP7516007B2 JP7516007B2 (ja) | 2024-07-16 |
Family
ID=60787676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567628A Active JP7516007B2 (ja) | 2016-06-28 | 2017-06-28 | 経口抗生物質からのマイクロバイオーム防御 |
| JP2022074289A Active JP7530933B2 (ja) | 2016-06-28 | 2022-04-28 | 経口抗生物質からのマイクロバイオーム防御 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022074289A Active JP7530933B2 (ja) | 2016-06-28 | 2022-04-28 | 経口抗生物質からのマイクロバイオーム防御 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11517614B2 (enExample) |
| EP (1) | EP3474885B8 (enExample) |
| JP (2) | JP7516007B2 (enExample) |
| CN (1) | CN109562147B (enExample) |
| CA (1) | CA3029469A1 (enExample) |
| WO (1) | WO2018005606A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3468573T (pt) | 2016-06-14 | 2023-10-16 | Vedanta Biosciences Inc | Tratamento de uma infeção por clostridium difficile |
| US12161680B2 (en) | 2018-08-17 | 2024-12-10 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| ES2994844T3 (en) * | 2018-12-07 | 2025-02-03 | Tillotts Pharma Ag | Colonic drug delivery formulation |
| EP3662901B1 (en) | 2018-12-07 | 2025-01-01 | Tillotts Pharma AG | Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing |
| EP3662900A1 (en) * | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Colonic drug delivery formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2081557A1 (en) * | 2006-11-17 | 2009-07-29 | DA Volterra | Colonic delivery using zn/pectin beads with a eudragit coating. |
| US8273376B2 (en) | 2006-11-17 | 2012-09-25 | Da Volterra | Colonic delivery of metallo-dependent enzymes |
| FI119678B (fi) * | 2006-11-28 | 2009-02-13 | Ipsat Therapies Oy | Beta-laktamaasin käyttö |
| FI20105572A0 (fi) * | 2010-05-24 | 2010-05-24 | Prevab R Lcc | Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt |
| RU2015140610A (ru) | 2013-03-14 | 2017-04-17 | ТЕРАБАЙОМ, ЭлЭлСи | Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств |
| US9290754B2 (en) * | 2014-04-17 | 2016-03-22 | Synthetic Biologics Inc. | Beta-lactamases with improved properties for therapy |
| KR102467968B1 (ko) | 2014-10-08 | 2022-11-16 | 신세틱 바이오로직스, 인코퍼레이티드 | 베타-락타마제 제형 및 이의 용도 |
| WO2016137993A1 (en) | 2015-02-23 | 2016-09-01 | Synthetic Biologics, Inc. | Carbapenemases for use with antibiotics for the protection of the intestinal microbiome |
-
2017
- 2017-06-28 CN CN201780049843.2A patent/CN109562147B/zh active Active
- 2017-06-28 WO PCT/US2017/039672 patent/WO2018005606A1/en not_active Ceased
- 2017-06-28 US US16/313,488 patent/US11517614B2/en active Active
- 2017-06-28 JP JP2018567628A patent/JP7516007B2/ja active Active
- 2017-06-28 EP EP17821125.6A patent/EP3474885B8/en active Active
- 2017-06-28 CA CA3029469A patent/CA3029469A1/en active Pending
-
2022
- 2022-04-28 JP JP2022074289A patent/JP7530933B2/ja active Active
- 2022-10-26 US US18/049,791 patent/US11883474B2/en active Active
-
2023
- 2023-12-11 US US18/534,962 patent/US12274740B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523236A5 (enExample) | ||
| US10369111B2 (en) | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents | |
| ES2649063T3 (es) | Formulaciones farmacéuticas que contienen rifaximina, procedimientos para su obtención y método de tratamiento de la enfermedad intestinal | |
| JP3725542B2 (ja) | ピコサルフェート剤形 | |
| US11141440B2 (en) | Pharmaceutical oral formulation comprising bacteria | |
| RS54991B1 (sr) | Formulacije za oralnu isporuku adsorbenata u creva | |
| JP2018524354A (ja) | 大腸炎を処置する方法 | |
| RU2671400C2 (ru) | Фармацевтические композиции для лечения от helicobacter pylori | |
| JP2012520268A (ja) | グラム陰性細菌の除去のための組成物及び方法 | |
| RU2744576C2 (ru) | Пероральные фармацевтические композиции месалазина | |
| WO2014011564A2 (en) | Compositions and method for treatment and prophylaxis of inflammatory bowel disease | |
| WO2014011233A1 (en) | Compositions and method for treatment and prophylaxis of inflammatory bowel disease | |
| WO2018129061A1 (en) | Antimicrobial delivery system for the prevention and treatment of infections in the colon | |
| US11202772B2 (en) | Duloxetine sprinkles | |
| TWI536989B (zh) | 硝呋太爾用於製備治療梭菌屬種所引起之感染之藥物的用途 | |
| US20240374526A1 (en) | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |